^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TG6002
i
Other names: TG6002, VV-TK-RR-FCU1, VVWR-TK-RR-Fcu1, VVWR-TK-RR--Fcu1, T601, T 6011, T 601
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Tasly, Transgene
Drug class:
DNA synthesis inhibitor, Thymidylate synthase inhibitor
Related drugs:
1year
Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors. (PubMed, Mol Ther Oncolytics)
Viral replication, 5-fluorouracil synthesis, and tumor microenvironment changes were more frequently observed with higher TG6002 doses. This study confirmed the replicative properties, targeted chemotherapy synthesis, and reversion of the immunosuppressive tumor microenvironment in dogs with spontaneous malignant tumors treated with TG6002 and 5-fluorocytosine.
Journal • Oncolytic virus
|
5-fluorouracil • TG6002
over1year
Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. (clinicaltrials.gov)
P1/2, N=51, Terminated, Transgene | N=101 --> 51 | Trial completion date: Sep 2023 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Sep 2022 --> Feb 2023; Study has been terminated after Phase I part on 23 February 2023
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
|
TG6002
over1year
Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
P2a, N=15, Terminated, Transgene | N=75 --> 15 | Trial completion date: Sep 2023 --> Feb 2023 | Recruiting --> Terminated; Study has been terminated after Phase I part on 23 February 2023
Enrollment change • Trial completion date • Trial termination • Combination therapy • Metastases
|
TG6002
Share via
